efmarodocokin alfa   Click here for help

GtoPdb Ligand ID: 12212

Synonyms: IL-22Fc | RG 7880 | RG7880 | UTTR1147A
Compound class: Antibody
Comment: Efmarodocokin alfa is a recombinant human IL-22-Fc IgG4 fusion protein that acts as an agonist of the heterodimeric Interleukin-22α1/10β receptor which is expressed by epithelial cells. It activates the IL-22 signaling pathway without inducing systemic inflammation or causing immunosuppression. Efmarodocokin alfa was developed for potential to treat infectious or inflammatory diseases [2]. The most advanced investigation of its clinical utility has been of its potential to induce repair of the intestinal epithelial damage that is caused by inflammatory bowel diseases [1].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Efmarodocokin alfa was advanced to clinical studies to evaluate its potential to promote recovery of epithelial injury in patients with inflammatory bowel diseases, and seperately to prevent acute graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation. Wound-healing and repair potential is under investigation for intractable diabetic foot ulcers. Efmarodocokin alfa has also been evaluated for potential to treat hospitalised patients with severe coronavirus disease 2019 (COVID-19; which causes widespread epithelial injury in the lungs, vasculature and other tissues).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03558152 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC) Phase 2 Interventional Genentech, Inc.
NCT04539470 Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Phase 1 Interventional Genentech, Inc.
NCT04386616 A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia Phase 2 Interventional Genentech, Inc.